Over the last decade the non-small cell lung cancer therapeutics landscape has been dominated by the increasing focus on identification and validation of molecular targets as well as identification of the best candidate agents to address these targets. Among the notable successes has been the approval of erlotinib, gefitinib and afatinib for the EGF receptor (EGFR) mutation and more recently crizotinib for anaplastic lymphoma 
Introduction
Since the original report by Soda et al. that the anaplastic lymphoma kinase (ALK) gene fuses with the echinoderm microtubule-associated protein like 4 (EML4), resulting in potent transforming activity in non-small cell lung cancer (NSCLC) limited to the adenocarcinoma histologic subtype, it is well recognized that between 3 and 7% of NSCLC is molecularly defined by the presence of an inversion or translocation of chromosome 2p involving the ALK gene, resulting in a transforming fusion gene and represents a distinct molecular subset of disease (1, 2) . Generally, all so far identified ALK gene rearrangements are constituted by two portions. The first is the highly conserved break point within ALK, located in the intron immediately upstream of the exons encoding the kinase domain; the second is the 5'-end partners containing a coiled-coil or leucine zipper domain responsible for oligomerization of fusion protein and ligand-independent activation of the ALK TK activity. Constitutive activation of downstream signaling pathways, such as the Ras/MAPK, PI3K/AKT, and JAK/STAT, results in uncontrolled cancer cell proliferation and survival. Thirteen variants of the EML4-ALK fusion have been described, according to the break point on EML4 (from exon 2 to exon 20(3)). Furthermore, in addition to EML4, the TRK-fused gene (TFG (4) (5) (6) ) and the kinesin family member 5B (KIF5B (4-6)) have been described to be fused to ALK in rare cases (Table 1) .
Mice transduced with NIH3T3 cells forced to express EML4-ALK fusion gene can be successfully treated with ALK inhibitors (ALKi). Apart from the EML4-ALK fusion gene, 11 other variants have been identified but it is still unclear whether these result in differential susceptibility to ALKi (3) . In addition, chromosomal rearrangements involving Author Manuscript Published OnlineFirst on January 6, 2015; DOI: 10.1158/1078-0432.CCR- the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non-small-cell lung cancers that have shown sensitivity to ALKi in particular crizotinib (7) ( Table 1) .
The ALK tyrosine kinase inhibitor (ALK-TKI) crizotinib, which is a small molecule potent inhibitor targeting cMET, ALK and ROS1 tyrosine kinases, was the first in class shown to be effective for ALK-positive patients (ALK+) with advanced NSCLC demonstrating response rates of about 60% in a single-arm study which was grounds for accelerated FDA approval granted in October 2011 (8) (9) (10) . This study was followed by a randomized trial in which crizotinib demonstrated superiority over standard chemotherapy in patients previously treated with platinum-based chemotherapy. ALK inhibitors can inhibit ROS1 kinase activity in cell lines and crizotinib is also associated with clinically significant antitumor activity in patients with ROS1 NSCLC. A study investigating the use of crizotinib in ROS1 rearranged cancer demonstrated an overall response rate (ORR) of 72% (95% CI 58 to 84), with 33 partial responses (PR) and 3 complete responses (CR). Median duration of response was 17.6 months (95%CI, 14.4 to not reached), with 25 patients (50%) still in follow-up for progression at time of report.
The pharmacokinetics, antitumor activity and safety profile of crizotinib in this group of patients were similar to those observed in patients with ALK-positive NSCLC (7).
Despite dramatic initial activity of crizotinib in ALK+ NSCLC, invariably crizotinib resistance develops typically within 1-2 years from beginning of treatment. The central nervous system (CNS) is a particularly common site of progressive disease in crizotinibtreated patients, suggesting the need for ALKi that not only can overcome acquired crizotinib resistance but also penetrate the blood-brain barrier (11, 12) . This review Ceritinib led to suppression of ALK phosphorylation as well as the downstream PI3K-AKT, MEK-ERK, and mTOR signaling pathways at lower doses than crizotinib.
Whereas ceritinib was potent against the two lung cancer cell lines with ALK rearrangements, it was not potent against NSCLC or breast cancer cell lines driven by KRAS, EGFR, PI3K,or HER2 (13),In addition, in treatment-naïve H228 xenograft models, ceritinib demonstrated more durable antitumor activity than crizotinib (13) . The kinase selectivity has been tested in a cellular proliferation assay against 16 different kinases, and aside from ALK, no inhibition below 100 nmol/L was observed (14) . Unlike crizotinib, ceritinib does not inhibit the activity of MET, a tyrosine kinase that can be At the time of data cutoff, the majority of these patients were still receiving ceritinib and median PFS had not been reached.
In the 124 patients who started the study with brain metastases, ceritinib achieved an ORR of 54.0% (95% CI = 44.9%-63.0%) and a median PFS of 6.9 months (95% CI = 5.4-8.4). Tumor shrinkage was seen in patients with brain metastases with (50%; 95% CI = 39.7%-60.3%) and without (69.2%; 95% CI = 48.2%-85.7%) prior ALK-TKI. Discontinuation of treatment due to adverse events occurred in 10% of patients, and 59% of patients required at least one dose reduction. The most common adverse events, occurring in more than half of patients, were diarrhea, nausea, vomiting, abdominal pain, and fatigue (15, 16) . The subgroup analysis between Asian and Caucasian patients showed that baseline demographics were similar but ALKi pretreatment had been received by 47 (29%) and 108 (66%) pts, respectively (17) . Of 173 patients analyzed for efficacy the ORR was 69% (95% CI: 55.2, 80.9) in Asian patients (38/55) and 57% (95% CI: 47.3, 65.9) in Caucasian patients (67/118). The median duration of response (DOR) among responders was 10.1 months (95% CI: 7.3, not reached) and 6.9 months (95% CI: 4.5, 11.4) in the Asian and Caucasian patients, respectively. The observed differences between Asians and Caucasians for ORR and DOR were not explained by differences in ALKi pretreatment (17) .
Two Phase III, ongoing, randomized trials are currently investigating the role of ceritinib both in chemotherapy and crizotinib previously treated (NCT01828112) ALK+ NSCLC versus single agent chemotherapy (pemetrexed or docetaxel), and in previously untreated (NCT01828099) ALK+ NSCLC versus platinum doublet chemotherapy (platinum/pemetrexed).
Ceritinib Toxicity Profile
Adverse reaction data are based on 255 patients treated with ceritinib 750 mg daily for ALK+ malignancies (n =246 NSCLC; n = 9 other ALK+ diseases) (16, 18) .
Serious adverse events (AE) were rare (≤2%), and included interstitial lung disease (ILD)/pneumonitis, convulsion, pneumonia, dyspnea, dehydration, hyperglycemia and nausea (18) . The most common AE (≥1%) that resulted in discontinuation of therapy included ILD/pneumonitis, pneumonia and anorexia. Fatal AE were also rare (5% of patients) resulting from pneumonia (n = 4), respiratory failure (n = 1), ILD/pneumonitis (n = 1), pneumothorax (n = 1), gastric hemorrhage (n =1), general physical health Concentration-dependent QTc prolongation has also occurred (18) .
Mechanisms of Resistance to ALK Inhibitors
Mechanisms of acquired resistance are heterogeneous and may evolve dynamically in response to different ALK-TKIs and may be divided into 2 groups: ALK-dominant or ALK-nondominant (Table 1) . ALK-dominant mechanisms include second mutations and C1156Y, within the kinase domain of the EML4-ALK fusion gene in the same patient who acquired resistance to crizotinib (19) . L1196M is a gatekeeper mutation that interferes with the binding of crizotinib. Other resistance mutations in the ALK gene have been discovered in the clinical setting or in mutagenesis screening, including L1152R, 1151Tins, G1202R, S1206Y, F1174C, D1203N, G1269A, and L1196M. 11 ALK+ with NSCLC with acquired resistance to crizotinib were reported to exhibit newonset ALK copy number gain, which may occur in combination with resistance mutations.
The known ALK-nondominant mechanisms leading to crizotinib resistance are mutations of other oncogenes such as the EGFR and KRAS genes (19) , amplification of the KIT gene (20) , increased autophosphorylation of EGFR (20) , and transformation to sarcomatoid carcinoma (21) ( Second-generation ALKi, such as alectinib (24, 25) and ceritinib (14) , have been shown to be effective not only in crizotinib-naive patients but also in those resistant to crizotinib.
Unfortunately ceritinib resistance has already been reported in 11 ALK+ NSCLC by fluorescent in situ hybridization (FISH) showing mutations in 2 residues G1202R and F1174C respectively in 3 out of 11 and 2 out of 11 post-ceritinib biopsies (13) . In vitro resistance to both crizotinib and ceritinib was reported in less common ALK-resistance mutations such as C1156Y, 1151T-ins and L1152P (13) .
A novel ALK V1180L gatekeeper mutation from a cell line model and a second novel I1171T mutation from a patient who developed resistance to alectinib were recently reported (26) . Both mutations demonstrated structural alterations with subsequent decrease binding affinity with alectinib and crizotinib. However, both Intriguingly, no progression of CNS lesions was observed in 15 patients proved to harbor brain metastases by the time of data cutoff. The PFS at 1 year was 83% (95% CI, 68-92), although the median PFS was not reached.
Results from 47 patients enrolled in another phase I/II study, showed alectinib to be well tolerated, with the most common AE being fatigue (30%), myalgia (17%), and peripheral edema (17%). Dose-limiting toxic effects were recorded in 2 patients in the cohort receiving alectinib 900 mg twice a day. At data cut-off (median follow-up 126 days), investigator-assessed OR were noted in 24/44 (55%) patients, with a confirmed CR in 1 (2%), a confirmed PR in 14 (32%), and an unconfirmed PR in 9 (20%). 16 (36%) patients had stable disease (SD); the remaining 4 (9%) had progressive disease (PD).
Of 21 patients with CNS metastases at baseline, 11 (52%) OR, 6 (29%) CR (3 unconfirmed), 5 (24%) PR (1 unconfirmed), 8 (38%) SD and the remaining 2 (10%) PD were reported. Alectinib 600 mg twice a day was chosen as the recommended dose for phase 2 (27) .
AP26113 is a novel TKI that potently inhibits mutant activated forms of the ALK and EGFR genes as well as TKI-resistant forms, including L1196M of the ALK gene and T790M of the EGFR gene (28) . Preliminary data for an ongoing dose-finding phase I/II study of AP26113 for advanced malignancy refractory to standard treatment showed the efficacy and safety of the compound in patients with NSCLC previously treated with ALK inhibitors or EGFR-TKIs. Among 57 evaluable ALK+ NSCLC patients, 41 (72%) responded. 
Among 51 evaluable ALK+ NSCLC with prior crizotinib exposure, 35 (69%) responded. Duration of response was 1.6 to 14.7 months ongoing at the time of data cut-off. Among 49 patients with follow-up scans, median PFS was 10.9 months. Nine out of 13 ALK+ with untreated progressing CNS lesions at baseline and with follow-up scans had evidence of radiographic improvement in CNS, including one patient with improvement in leptomeningeal disease (29) . The antitumor activity of at least 2 other second-generation ALKi, ASP3026 and X-396, has been shown in vitro studies, and these are currently under clinical investigation (NCT01401504 and NCT01625234). Table 2 summarize the trials with novel second generation ALK-inhibitors in clinical development.
ALK-Fusion Detection Methods
ALK gene fusion can be detected by several methods, including RT-PCR, the first published method used (2); FISH, the currently accepted method approved by the FDA; and IHC.
FISH is a relatively expensive assay that is able to detect all types of ALK rearrangements known to date, however its interpretation could be challenging even in the hands of experienced specialists. IHC is relatively inexpensive, fast, and familiar to most pathologists, can also be used universally, similar to FISH, as it can potentially detect overexpressed ALK chimeric protein produced by any rearrangement type. The concept of co-approval of therapeutic product and companion diagnostics has been encouraged as part of the strategy to promote personalized medicine (31) .
However molecular diagnostic testing is complex and several assays with different merits may be suitable in that regard especially when testing molecularly heterogeneous tumors such as NSCLC.
When to Use Ceritinib in ALK-Positive NSCLC
The optimal choice for first line therapy for ALK+ as well as the optimal sequence for therapies after progression to front-line therapy aiming at maximizing survival benefit and strategies to prevent or delay resistance remains to be determined. Although it is Author Manuscript Published OnlineFirst on January 6, 2015; DOI: 10.1158/1078-0432.CCR- not clear at present whether crizotinib or second-generation ALKi will be the superior treatment for ALK+ patients, a head to-head study comparing crizotinib with the secondgeneration ALKi would clarify this point. In fact, a randomized phase III trial comparing alectinib with crizotinib is currently being performed to address this issue (NCT02075840). The activity demonstrated by ceritinib and alectinib in patients with CNS disease involvement, suggests use of these agents preferentially in this clinical scenario.
Based on already described mechanisms of resistance to first and secondgeneration ALKi specific treatment strategies with combination therapy with EGFR-TKI, KIT-TKI, MET-TKI or pemetrexed-based therapy could be explored.
Conclusions and Challenges
The challenge of future studies is in the identification of the mechanisms underlying acquired resistance to ceritinib and new ALKi. In addition, combination between ALKi and other therapeutic strategies, such as inhibition of escape survival pathways and immunotherapy agents are potential alternatives to increase survival in ALK+ NSCLC patients. 
